A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study-Reference-Cited by-同舟云学术

A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study

Published:2014-03 Issue: Volume:66 Page:S8-S9
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

De Benedetti Fabrizio¹,Ruperto Nicolino²,Brunner Hermine³,Grom Alexei A.⁴,Wulffraat Nico²,Henrickson Michael⁴,Jerath Rita⁴,Kimura Yuki⁴,Kadva Alysha K.⁵,Wang Jianmei⁶,Martini Alberto²,Lovell Daniel J.³

Affiliation:

1. IRCCS Ospedale Pediatrico Bambino Gesù; Rome Italy

2. PRINTO; Genoa Italy

3. Cincinnati Children's Hospital Medical Center; Cincinnati OH

4. PRCSG; Cincinnati OH

5. Genentech, Inc.; South San Francisco CA

6. Roche Products Ltd.; Welwyn Garden City United Kingdom

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of an early response‐based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis;International Journal of Rheumatic Diseases;2024-05

2. A rare simultaneous presentation of combined occlusion and optic neuritis in a lupus erythematosus patient with anti-phospholipid antibody syndrome;Lupus;2023-04-14

3. Experience of Long-Term (9 Years) Administration of Tocilizumab in Female Patient with Systemic Onset Juvenile Arthritis: Case Study;Current Pediatrics;2022-07-14

4. Association of antiphospholipid antibodies with clinical activity and renal pathological activity in patients with lupus nephritis;Lupus;2021-04-08

5. Antiphospholipid antibodies in patients with proliferative and membranous lupus nephritis;Clinical Rheumatology;2020-01-13